Skip to main
EVAX
EVAX logo

EVAX Stock Forecast & Price Target

EVAX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evaxion AS demonstrates a robust financial outlook, bolstered by Merck's (MRK) option exercise, which extends the company's cash runway into the first half of 2027, enabling progress on key milestones in its infectious disease and oncology pipelines. The extension and expansion of the EVX-B2 program's review by MRK is indicative of a strengthened likelihood for potential in-licensing, enhancing strategic partnerships and validation of Evaxion's AI-Immunology platform. Furthermore, the increasing collaboration with MRK, which holds approximately 20% ownership in Evaxion, underscores confidence in the company's innovative approaches to developing novel immunotherapies, further enhancing its market positioning.

Bears say

Evaxion AS faces a concerning outlook due to its reliance on unproven AI technology in the highly competitive biotech sector, which may delay the development and possible commercialization of its personalized vaccines and immunotherapies. Furthermore, the company's financial position appears strained, with limited cash reserves and significant ongoing expenses related to research and development, heightening risks associated with funding its clinical and preclinical pipelines. Additionally, challenges related to regulatory approvals and market adoption of novel therapies may impede revenue generation, further contributing to a negative financial outlook.

EVAX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evaxion Biotech A/S (EVAX) Forecast

Analysts have given EVAX a Strong Buy based on their latest research and market trends.

According to 2 analysts, EVAX has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evaxion Biotech A/S (EVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.